Literature DB >> 8496973

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.

J G Tibben, O C Boerman, R A Claessens, F H Corstens, M van Deuren, P H de Mulder, J W van der Meer, K G Keijser, L F Massuger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8496973     DOI： 10.1093/jnci/85.12.1003

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

1.  Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Authors:  Tong Zhang; Charles L Sentman
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

Review 2.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

3.  CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.

Authors:  G C de Gast; I A Haagen; A A van Houten; S C Klein; A J Duits; R A de Weger; T M Vroom; M R Clark; J Phillips; A J van Dijk
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

4.  Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo.

Authors:  M B Moreno; J A Titus; M S Cole; J Y Tso; N Le; C H Paik; T Bakács; C M Zacharchuk; D M Segal; J R Wunderlich
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

5.  A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

Authors:  M Mack; G Riethmüller; P Kufer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

6.  Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies.

Authors:  Ho Young Lee; Edward Contreras; Ames C Register; Qiang Wu; Kathleen Abadie; Khristofer Garcia; Pin Yee Wong; Guoying Jiang
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

7.  Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

Authors:  R M Luiten; L R Coney; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

8.  Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

Authors:  B J Kroesen; J Buter; D T Sleijfer; R A Janssen; W T van der Graaf; T H The; L de Leij; N H Mulder
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

9.  Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

Authors:  R A Janssen; B J Kroesen; J Buter; G Mesander; D T Sleijfer; T H The; N H Mulder; L de Leij
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.